Natera Partners With Susan G. Komen to Advance Breast Cancer Awareness
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
CAMBRIDGE, UK and INDIANAPOLIS, IN — August 26, 2026 4basebio PLC and Genezen announced an expanded, non-exclusive strategic collaboration...
St. Paul, Minnesota, August,11, 2026 Zepto Life Technology has been awarded a contract valued at up to $8.9 million...
AUSTIN, Texas, August 5, 2026 Natera, Inc. has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...
DURHAM, N.C., July 8, 2026 GeneCentric has announced the launch of ExpressCT Rewind™, a retrospective fragmentomics analysis service designed...
PALO ALTO, California, May 28, 2026 DELFI Diagnostics has achieved a significant regulatory milestone after receiving a Clinical Laboratory...
Austin, Texas, USA – May 21, 2026 Natera, Inc., a global leader in cell-free DNA testing and precision medicine,...
